W. Fraser Symmans

48.7k total citations · 12 hit papers
323 papers, 25.7k citations indexed

About

W. Fraser Symmans is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, W. Fraser Symmans has authored 323 papers receiving a total of 25.7k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Cancer Research, 180 papers in Oncology and 104 papers in Molecular Biology. Recurrent topics in W. Fraser Symmans's work include Breast Cancer Treatment Studies (166 papers), HER2/EGFR in Cancer Research (84 papers) and Cancer Genomics and Diagnostics (79 papers). W. Fraser Symmans is often cited by papers focused on Breast Cancer Treatment Studies (166 papers), HER2/EGFR in Cancer Research (84 papers) and Cancer Genomics and Diagnostics (79 papers). W. Fraser Symmans collaborates with scholars based in United States, France and Germany. W. Fraser Symmans's co-authors include Lajos Pusztai, Gabriel N. Hortobágyi, Jeffrey S. Ross, Vicente Valero, Kenneth R. Hess, Ana M. González-Angulo, Massimo Cristofanilli, Fabrice André, Marjorie Green and James Stec and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

W. Fraser Symmans

317 papers receiving 25.1k citations

Hit Papers

Response to Neoadjuvant Therapy and Long-Term Survival in... 2005 2026 2012 2019 2008 2005 2007 2009 2020 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
    2008 2.2k citations Cornelia Liedtke, Chafika Mazouni et al. Journal of Clinical Oncology profile →
  2. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
    2005 1.4k citations Roman Rouzier, Charles M. Perou et al. Clinical Cancer Research profile →
  3. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
    2007 1.1k citations W. Fraser Symmans, Florentia Peintinger et al. Journal of Clinical Oncology profile →
  4. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
    2009 885 citations Jeffrey S. Ross, W. Fraser Symmans et al. profile →
  5. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    2020 851 citations Jane Perlmutter, Charles M. Perou et al. Journal of Clinical Oncology profile →
  6. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    2021 592 citations W. Fraser Symmans et al. Journal of Clinical Oncology profile →
  7. Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
    2006 553 citations Kenneth R. Hess, K. Anderson et al. Journal of Clinical Oncology profile →
  8. Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
    2013 525 citations Ana M. González-Angulo, Funda Meric‐Bernstam et al. Clinical Cancer Research profile →
  9. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
    2018 516 citations Joyce O’Shaughnessy, Norman Wolmark et al. profile →
  10. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
    2017 417 citations W. Fraser Symmans, Rebekah Gould et al. Journal of Clinical Oncology profile →
  11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
    2017 337 citations Miguel Martín, W. Fraser Symmans et al. profile →
  12. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
    2018 237 citations W. Fraser Symmans et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Fraser Symmans United States 78 14.5k 14.3k 8.2k 4.6k 3.9k 323 25.7k
Soonmyung Paik United States 53 13.3k 0.9× 13.4k 0.9× 6.0k 0.7× 5.5k 1.2× 3.5k 0.9× 169 23.4k
Jonas Bergh Sweden 73 15.6k 1.1× 11.6k 0.8× 11.2k 1.4× 2.8k 0.6× 4.9k 1.3× 521 29.1k
Ayşegül A. Şahin United States 87 12.1k 0.8× 10.2k 0.7× 9.0k 1.1× 5.7k 1.2× 3.2k 0.8× 389 25.3k
Gϋnter von Minckwitz Germany 78 16.4k 1.1× 13.2k 0.9× 4.2k 0.5× 4.9k 1.1× 3.9k 1.0× 428 25.0k
Ana M. González-Angulo United States 83 15.2k 1.0× 11.4k 0.8× 8.9k 1.1× 3.8k 0.8× 5.2k 1.3× 281 25.2k
Torsten O. Nielsen Canada 77 16.1k 1.1× 14.5k 1.0× 10.3k 1.3× 4.9k 1.0× 7.7k 2.0× 241 31.1k
Lajos Pusztai United States 87 20.1k 1.4× 16.9k 1.2× 12.1k 1.5× 4.2k 0.9× 5.7k 1.5× 591 35.0k
Stefanie S. Jeffrey United States 51 13.8k 1.0× 14.9k 1.0× 16.6k 2.0× 4.2k 0.9× 3.9k 1.0× 138 33.6k
Maggie C.U. Cheang United States 47 12.6k 0.9× 12.4k 0.9× 7.4k 0.9× 3.4k 0.7× 4.0k 1.0× 122 21.3k
Lars A. Akslen Norway 67 14.0k 1.0× 11.6k 0.8× 13.8k 1.7× 3.3k 0.7× 4.4k 1.1× 314 29.1k

Countries citing papers authored by W. Fraser Symmans

Since Specialization
Citations

This map shows the geographic impact of W. Fraser Symmans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Fraser Symmans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Fraser Symmans more than expected).

Fields of papers citing papers by W. Fraser Symmans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Fraser Symmans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Fraser Symmans. The network helps show where W. Fraser Symmans may publish in the future.

Co-authorship network of co-authors of W. Fraser Symmans

This figure shows the co-authorship network connecting the top 25 collaborators of W. Fraser Symmans. A scholar is included among the top collaborators of W. Fraser Symmans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Fraser Symmans. W. Fraser Symmans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Suman, Vera J., Lili Du, Tanya L. Hoskin, et al.. (2022). Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clinical Cancer Research. 28(15). 3287–3295. 12 indexed citations
3.
Lau, Rosanna, Lili Du, Eveline Chen, et al.. (2020). Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clinical Chemistry. 66(7). 934–945. 7 indexed citations
4.
Pusztai, Lajos, Stacy L. Moulder, Mehmet Altan, et al.. (2014). Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research. 20(20). 5265–5271. 28 indexed citations
5.
González-Angulo, Ana M., Takayuki Iwamoto, Shuying Liu, et al.. (2012). Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer. Clinical Cancer Research. 18(4). 1109–1119. 51 indexed citations
6.
Dutta, Bhaskar, Lajos Pusztai, Yuan Qi, et al.. (2012). A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. British Journal of Cancer. 106(6). 1107–1116. 37 indexed citations
7.
Santarpia, Libero, Yuan Qi, Katherine Stemke‐Hale, et al.. (2012). Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment. 134(1). 333–343. 94 indexed citations
8.
Coutant, Charles, Roman Rouzier, Yuan Qi, et al.. (2011). Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. Clinical Cancer Research. 17(8). 2591–2601. 44 indexed citations
9.
Kuerer, Henry M., Aman U. Buzdar, Elizabeth A. Mittendorf, et al.. (2010). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 117(1). 39–47. 48 indexed citations
10.
Tabchy, Adel, Vicente Valero, Tatiana Vidaurre, et al.. (2010). Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research. 16(21). 5351–5361. 160 indexed citations
11.
Moulder, Stacy, Kai Yan, Fei Huang, et al.. (2010). Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. Molecular Cancer Therapeutics. 9(5). 1120–1127. 27 indexed citations
12.
Pusztai, Lajos, Jong‐Hyeon Jeong, Yun Yun Gong, et al.. (2009). Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. Journal of Clinical Oncology. 27(26). 4287–4292. 72 indexed citations
13.
Liedtke, C, Kristine Broglio, Stacey Moulder, et al.. (2009). Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Annals of Oncology. 20(12). 1953–1958. 228 indexed citations
14.
André, Fabrice, Bastien Job, Philippe Dessen, et al.. (2009). Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. Clinical Cancer Research. 15(2). 441–451. 248 indexed citations
15.
Liedtke, Cornelia, Luca Cardone, Attila Tordai, et al.. (2008). PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer. Breast Cancer Research. 10(2). R27–R27. 49 indexed citations
16.
André, Fabrice, Chafika Mazouni, Cornelia Liedtke, et al.. (2007). HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Research and Treatment. 108(2). 183–190. 80 indexed citations
17.
18.
Symmans, W. Fraser, Florentia Peintinger, Christos Hatzis, et al.. (2007). Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal of Clinical Oncology. 25(28). 4414–4422. 1078 indexed citations breakdown →
19.
Rouzier, Roman, Charles M. Perou, W. Fraser Symmans, et al.. (2005). Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research. 11(16). 5678–5685. 1414 indexed citations breakdown →
20.
Symmans, W. Fraser, et al.. (1995). Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions. Human Pathology. 26(2). 210–216. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Soonmyung Paik Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Ayşegül A. Şahin Breakdown of academic impact, for papers by Gϋnter von Minckwitz Breakdown of academic impact, for papers by Ana M. González-Angulo Breakdown of academic impact, for papers by Torsten O. Nielsen Breakdown of academic impact, for papers by Lajos Pusztai Breakdown of academic impact, for papers by Stefanie S. Jeffrey Breakdown of academic impact, for papers by Maggie C.U. Cheang Breakdown of academic impact, for papers by Lars A. Akslen
Rankless by CCL
2026